Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone857-259-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.20 million
Profitability
Miscellaneous
Employees115
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics Inc (NASDAQ:JNCE) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.07. The business had revenue of $10.98 million for the quarter, compared to analysts' expectations of $14.75 million. Jounce Therapeutics had a negative return on equity of 26.05% and a negative net margin of 41.13%. View Jounce Therapeutics' Earnings History.
When is Jounce Therapeutics' next earnings date?
What guidance has Jounce Therapeutics issued on next quarter's earnings?
Jounce Therapeutics updated its FY 2019 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50-60 million, compared to the consensus revenue estimate of $58.34 million.
What price target have analysts set for JNCE?
4 equities research analysts have issued twelve-month target prices for Jounce Therapeutics' stock. Their forecasts range from $10.00 to $13.00. On average, they anticipate Jounce Therapeutics' stock price to reach $11.6667 in the next year. This suggests a possible upside of 163.4% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.
What is the consensus analysts' recommendation for Jounce Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.
Has Jounce Therapeutics been receiving favorable news coverage?
News headlines about JNCE stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Jounce Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Jounce Therapeutics.
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include Heska (HSKA), Translate Bio (TBIO), Scholar Rock (SRRK), DBV TECHNOLOGIE/S (DBVT), Mesoblast (MESO), BioCardia (BCDA), Krystal Biotech (KRYS), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), BioCryst Pharmaceuticals (BCRX), Tcr2 Therapeutics (TCRR), Acorda Therapeutics (ACOR), Agenus (AGEN), PDL BioPharma (PDLI) and Gritstone Oncology (GRTS).
What other stocks do shareholders of Jounce Therapeutics own?
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 60)
- Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
- Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
- Dr. James P. Allison, Founder
- Dr. Thomas F. Gajewski, Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Who are Jounce Therapeutics' major shareholders?
Jounce Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (4.56%), BlackRock Inc. (3.47%), Dimensional Fund Advisors LP (1.96%), AQR Capital Management LLC (1.17%), Acadian Asset Management LLC (0.88%) and JPMorgan Chase & Co. (0.85%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.
Which major investors are selling Jounce Therapeutics stock?
JNCE stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Renaissance Technologies LLC, Morgan Stanley, Spark Investment Management LLC, Alambic Investment Management L.P., Wellington Management Group LLP, Wells Fargo & Company MN and California State Teachers Retirement System. View Insider Buying and Selling for Jounce Therapeutics.
Which major investors are buying Jounce Therapeutics stock?
JNCE stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Oxford Asset Management LLP, BlackRock Inc., Man Group plc and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Jounce Therapeutics.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $4.43.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $146.06 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.
What is Jounce Therapeutics' official website?
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
